Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.

PubWeight™: 0.79^‹?›

🔗 View Article (PMID 25349975)

Published in Br J Cancer on October 28, 2014

Authors

M Koczywas¹, P H Frankel², T W Synold³, H-J Lenz⁴, J E Mortimer¹, A B El-Khoueiry⁴, D R Gandara⁵, M C Cristea¹, V M Chung¹, D Lim¹, K L Reckamp¹, D H Lau⁵, L A Doyle⁶, C Ruel², M I Carroll⁷, E M Newman³

Author Affiliations

1: Department of Medical Oncology, City of Hope, Duarte, CA, USA.
2: Department of Information Sciences, City of Hope, Duarte, CA, USA.
3: Department of Molecular Pharmacology, City of Hope National Medical Center, Duarte, CA, USA.
4: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
5: Medical Center, UC Davis Comprehensive Cancer Center, Sacramento, CA, USA.
6: Investigational Drug Research, National Cancer Institute, Rockville, MD, USA.
7: Department of Research-RN, City of Hope, Duarte, CA, USA.

Articles citing this ↘

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health (2015) 0.82

Eribulin in Cancer Treatment. Mar Drugs (2015) 0.80

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium. Br J Cancer (2015) 0.76

Articles cited by this ↗

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73

Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol (2006) 2.93

The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther (2005) 2.70

In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res (2001) 2.62

Phase I study of eribulin mesylate administered once every 21 days in patients with advanced solid tumors. Clin Cancer Res (2009) 2.03

A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97

Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res (2004) 1.81

Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol (2006) 1.42

Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15

Cisplatin nephrotoxicity. Toxicol Lett (1989) 1.15

Neurotoxicity caused by the treatment with platinum analogues. Chemother Res Pract (2011) 1.12

Broad spectrum preclinical antitumor activity of eribulin (Halaven(R)): optimal effectiveness under intermittent dosing conditions. Anticancer Res (2012) 1.02

Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells. J Natl Cancer Inst Monogr (1993) 0.92